Every 10-Q that Lexicon Pharmaceuticals, Inc. (LXRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LXRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LXRX filings page.
Lexicon Pharmaceuticals, Inc. reported total revenues of $0.7 million for the quarter ended June 30, 2026, down from $28.9 million a year earlier, as the prior-year period included substantial licensing revenue from its Novo Nordisk agreement. Six‑month revenues were $21.8 million versus $30.1 million in 2025, with 2026 including $20 million of Novo Nordisk development milestones and modest INPEFA product sales. The company recorded a net loss of $31.8 million ($0.07 per share) in Q2 2026 versus net income of $3.3 million in Q2 2025, and a six‑month net loss of $32.8 million ($0.08 per share) versus a $22.0 million loss a year earlier.
As of June 30, 2026, Lexicon held $190.6 million in cash, cash equivalents, short‑term investments and restricted cash, up from $125.2 million at year‑end 2025, after using $23.9 million in operating cash in the first half. Liquidity was strengthened by approximately $96.2 million of net proceeds from February 2026 common and Series B preferred stock issuances and a new $100 million Hercules Term Loan, of which $55 million was initially funded and largely used to repay $54.3 million of Oxford term loans, generating a $4.3 million loss on early extinguishment and eliminating a $29 million restricted‑cash requirement. The Hercules facility bears interest at a floor rate of 9.85% and matures in 2030.
Strategically, Lexicon continues U.S. commercialization of INPEFA for heart failure and advances its pipeline: the SONATA‑HCM Phase 3 trial of sotagliflozin in hypertrophic cardiomyopathy, regulatory efforts for ZYNQUISTA in type 1 diabetes including ongoing Notice of Opportunity for Hearing proceedings and potential NDA resubmission supported by third‑party safety data, and partnering discussions for pilavapadin after positive Phase 2 data in diabetic peripheral neuropathic pain. LX9851, licensed to Novo Nordisk, is in Phase 1 for obesity. Management notes it has incurred an accumulated deficit of about $2.1 billion and states that while current cash and expected collaboration revenues are believed sufficient for at least the next 12 months, additional capital and collaborations will be needed over time, particularly to fund Phase 3 development of pilavapadin.
Lexicon Pharmaceuticals reported sharply improved Q1 2026 results. Revenue rose to $21.1 million from $1.3 million, driven mainly by $20.0 million of development milestone revenue from its Novo Nordisk licensing agreement, alongside modest INPEFA net product sales of $1.1 million.
Net loss narrowed to $1.0 million, or less than $0.01 per share, compared with a $25.3 million loss a year earlier, as both research and development and selling, general and administrative expenses declined. Operating cash outflow was $14.7 million, but total cash, cash equivalents, short‑term investments and restricted cash increased to $199.7 million as of March 31, 2026, helped by approximately $96.5 million of February common and preferred stock issuances.
The company highlighted progress across its pipeline, including the SONATA‑HCM Phase 3 trial of sotagliflozin, ongoing efforts to potentially resubmit the ZYNQUISTA NDA for type 1 diabetes, Fast Track‑designated pilavapadin in diabetic peripheral neuropathic pain, and Novo Nordisk’s Phase 1 work on LX9851. Management believes current liquidity, collaborations and a new $100 million Hercules loan facility support operations for at least the next 12 months.
Lexicon Pharmaceuticals (LXRX) filed its Q3 2025 10‑Q, reporting total revenues of $14.2 million, driven largely by $13.2 million in licensing revenue from its Novo Nordisk agreement. Net product revenue from INPEFA® was $1.0 million. The company posted a net loss of $12.8 million, a substantial improvement from a loss of $64.8 million a year ago, as operating expenses fell sharply following late‑2024 restructuring.
Cash, cash equivalents, restricted cash and short‑term investments totaled $145.0 million as of September 30, 2025, including $29.0 million in restricted cash tied to debt covenants. Lexicon repaid $45.0 million on its Oxford term loans in April, leaving $56.5 million in long‑term debt (carrying value) and a weighted average interest rate of 11.8%. The Novo Nordisk license delivered $40.7 million in year‑to‑date licensing revenue; $4.3 million of the $45.0 million upfront remained as deferred revenue at quarter‑end. The company maintains a $75 million at‑the‑market equity program available.